As Centers for Medicare and Medicaid Services (CMS) prepares to announce the final coverage decision for a revolutionary new Alzheimer’s drug, a paper from Biogen and …
Real-world data is critical for new Alzheimer’s drug, says paper Read More »
Reauthorization of FDA user fee agreements will strengthen dialogue and advance innovation, BIO’s Chief Scientific Officer Dr. Cartier Esham told the Senate Health, Education, Labor …
BIO’s CSO tells Senate PDUFA is ‘critical to advancing innovation’ Read More »
Some lawmakers and activists are trying to use the Bayh-Dole Act of 1980 and its “march-in” authority to seize the patent rights for a prostate …
Other Voices: There are unintended costs of federal efforts to control drug prices Read More »
The Biden administration announced it is considering lifting summertime restrictions on the sales of E15 automotive fuel, to help alleviate the rapid clmb of gasoline …
Biofuels can help battle surging gas prices and emissions, BIO tells Biden Read More »
The life-sized, 3D-printed statues of 125 women who filled the garden at the the Smithsonian Institution in March were from the traveling #IfThenSheCan Exhibit, which …
#IfThenSheCan: Exhibit meant to inspire the next generation of women in STEM Read More »
Science supported by the government can help in the effort to control climate change, according to testimony provided last week to the House Committee on …
LanzaTech testifies in Congress on government support for bioenergy Read More »
Stressing the seriousness of the threat that the antimicrobial resistance (AMR) poses to human health, U.S. Rep. Drew Ferguson, a sponsor of the PASTEUR act, …
Other Voices: US Rep. promotes public-private partnerships to combat AMR Read More »
A recent letter to U.S. Health and Human Services Secretary Xavier Becerra explains why a petition asking the government to “march in” on a a …
100 experts urge HHS to reject Bayh-Dole ‘march-in’ petition Read More »
Legislation to modernize the clinical drug development paradigm should be patient-centric, effective and inclusive, BIO’s Chief Scientific Officer Dr. Cartier Esham told a House panel …
BIO’s CSO testifies at congressional hearing on PDUFA riders Read More »
The Senate Finance Committee held a hearing yesterday on “prescription drug price inflation,” during which witnesses testified that price controls would limit biotechnology innovation in …
Video: Experts tell Senate drug price controls interfere with innovation, development Read More »
An opinion piece in the San-Jose Mercury News argues against forcing drug makers to allow for generic versions of their products simply because their research …
Other Voices: ‘Don’t sacrifice the miracle of American innovation’ Read More »
